Arbutus Biopharma (NASDAQ: ABUS)
Arbutus Biopharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Arbutus Biopharma Company Info
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
News & Analysis
Why Arbutus Biopharma Stock Is Sinking Today
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.
What's the Outlook for Arbutus Biopharma?
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.
Why Arbutus Biopharma Is Rocketing Higher Today
A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma.
Here's Why Arbutus Biopharma Fell Today
Short-term investors appear impatient.
3 Healthcare Stocks That Rocketed Higher in July
Here's what drove shares of these healthcare stocks through the roof last month.
Here's Why Arbutus Biopharma Corp. Is Tanking Today
The clinical-stage biotech reported good news and bad news -- with the bad outweighing the good.
Here's Why Arbutus Biopharma Corp. Stock Soared Today
A new drug candidate that licences Arbutus Biopharma's proprietary technology passed an important milestone.
The Single Greatest Mistake You Can Make When Investing in Biotech
Investing in biotech may look easy, but make this mistake and it could wind up costing you dearly.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.